AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29895309
Drug: Very high
RxNorm normalized name: Very high density lipoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very high intact-protein formula (VHPF) (8 g/100 kcal)
Trial: 14648210
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP regimen (doxorubicin 50 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, prednisolone 100 mg/body)
Trial: 14648210
Drug: THP-COP regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THP-COP regimen (pirarubicin 50 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2, prednisolone 100 mg/body)
Trial: 9329344
Drug: Dexamethasone (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (total dose, 10 mg/4 days)
Trial: 3948478
Drug: T3 administration
RxNorm normalized name: T3
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: T3 administration (30‐80 micrograms/day)
Trial: 25623343
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for insomnia (CBT-I)
Trial: 22998978
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with BBR and EZE
Trial: 15922565
Drug: Biological motion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological motion task
Trial: 2951178
Drug: porcine soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: porcine soluble and isophane, premixed porcine soluble/isophane, porcine soluble and lente, bovine ultralente with three porcine soluble injections before meals (all taken twice daily, and once daily for bovine ultralente)
Trial: 2951178
Drug: various insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: various insulin regimens
Trial: 30760277
Drug: alteplase-dose arm
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alteplase-dose arm of the ENCHANTED trial (HSRCs)
Trial: 25595117
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 200 mg tid
Trial: 15906123
Drug: Alvimopan 12
RxNorm normalized name: alvimopan 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alvimopan 12 mg
Trial: 11050374
Drug: 0.9% isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% isotonic saline infusion (control)
Trial: 11050374
Drug: 5.8% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.8% saline infusion with feedback from the right masseter sEMG
Trial: 11050374
Drug: 5.8% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.8% saline infusion with both sEMG and imEMG recorded
Trial: 6351890
Drug: Chlorpheniramine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine (4 mg)
Trial: 19417877
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium (25 mg)
Trial: 766800
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cyclophosphamide, methotrexate, 5-fluorouracil and vinblastine given intermittently
Trial: 28470676
Drug: NDI‐010976 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NDI‐010976 (20 mg)
Trial: 28470676
Drug: NDI‐010976 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NDI‐010976 (50 mg)
Trial: 28470676
Drug: NDI‐010976 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NDI‐010976 (200 mg)
Trial: 26385134
Drug: Room-temperature gel
RxNorm normalized name: ROOM DEODORIZER POWDER MENTOR #3202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room-temperature gel pack (20 °C)
Trial: 25004184
Drug: Citalopram as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram as adjunctive therapy to risperidone and olanzapine
Trial: 25004184
Drug: Reboxetine as
RxNorm normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine as adjunctive therapy to risperidone and olanzapine
Trial: 22798534
Drug: IV methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV methylprednisolone 2.5 mg/kg
Trial: 19650710
Drug: Intravitreal 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal 0.2 mL autologous plasmin enzyme (APE) injection
Trial: 19650710
Drug: Control eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control eye (no injection)
Trial: 14754695
Drug: Weekly courses
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly courses of betamethasone
Trial: 1565182
Drug: Erythropoietin therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin therapy
Trial: 31136656
Drug: High-fat load
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat load with fructose (3 doses of 50 g)
Trial: 31136656
Drug: High-fat load
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat load with glucose (3 doses of 50 g)
Trial: 25976238
Drug: Oral Morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Morphine Sulfate
Trial: 25976238
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of Phenobarbital followed by tapering dose
Trial: 22103649
Drug: Tooth-implant-supported fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tooth-implant-supported fixed prostheses (TISPs)
Trial: 22103649
Drug: Implant-supported prostheses
RxNorm normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported prostheses (ISPs)
Trial: 19563522
Drug: Disease-specific nutrition
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disease-specific nutrition treatment (standard diet plus a 400-mL oral supplement or specific enteral formula enriched with protein, 20% of total calories, arginine, zinc, and vitamin C)
Trial: 16389668
Drug: Hydroxyzine 25
RxNorm normalized name: hydroxyzine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 25 mg (HYD) with alcohol (ALC)
Trial: 16389668
Drug: Rupatadine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 20 mg (RUP) with alcohol (ALC)
Trial: 16389668
Drug: Rupatadine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 10 mg (RUP) with alcohol (ALC)
Trial: 16296259
Drug: Professional toothcleaning
RxNorm normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Professional toothcleaning (PTC), oral hygiene instruction, and motivation (test group)
Trial: 27372219
Drug: Nicotine patch
RxNorm normalized name: Nicotine Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patch treatment (21mg) with counseling for 8 weeks
Trial: 19819203
Drug: Neutral solution
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral solution
Trial: 17713794
Drug: Individual exercise
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual exercise therapy
Trial: 1787974
Drug: Clindamycin oral
RxNorm normalized name: clindamycin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin oral rinse
Trial: 6382127
Drug: Flubendazole (FZ)
RxNorm normalized name: flubendazole
DrugBank: Flubendazole (DB08974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flubendazole (FZ) treatment
Trial: 21440831
Drug: Topical phenylephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical phenylephrine (0.1 ml, 10%) administered twice in 5 minutes before surgery
Trial: 11122830
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m(2) every 3 weeks
Trial: 11122830
Drug: Docetaxel 100
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 100 mg/m(2)
Trial: 6873418
Drug: Treatment (Ps
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment (Ps and PA groups)
Trial: 22356584
Drug: Sertindole (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertindole (16 mg)
Trial: 17685733
Drug: Shared decision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shared decision making (SDM) program on antipsychotic drug choice
Trial: 12109619
Drug: Assessment of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assessment of peripheral insulin sensitivity using HOMA index and a novel index from OGTT
Trial: 16775680
Drug: NSAIDs (paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAIDs (paracetamol or parecoxib/valdecoxib) with piritramid
Trial: 12841663
Drug: Preoperative chemoradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemoradiation with 5-fluorouracil (350 mg/m2/day) and folinic acid (10 mg/m2) administered as intravenous bolus on days 1-5 and 29-33 of radiotherapy, followed by surgery after 4-6 weeks.
Trial: 10369641
Drug: Classical pedicle
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classical pedicle preparation technique (Group B)
Trial: 3492487
Drug: Ciprofloxacin 100
RxNorm normalized name: ciprofloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 100 mg
Trial: 2939794
Drug: Ciprofloxacin 150
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 150 mg
Trial: 2939794
Drug: Ciprofloxacin 200
RxNorm normalized name: ciprofloxacin 200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 200 mg
Trial: 29599611
Drug: Daclatasvir plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir plus asunaprevir (DUAL) - daclatasvir 60 mg once daily and asunaprevir 100 mg twice daily for 24 weeks
Trial: 29599611
Drug: Placebo (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (12 weeks) followed by DUAL treatment
Trial: 29599611
Drug: DUAL treatment
RxNorm normalized name: Meradimate/Octinoxate/Titanium Dioxide Topical application Lotion [PURPOSE DUAL TREATMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DUAL treatment during double-blind phase
Trial: 26913649
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K deficiency (PIVKA-II > 2 μg/L)
Trial: 18771374
Drug: Etoricoxib, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib, 120 mg/day for 7 days
Trial: 8388949
Drug: Dexamethasone (early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (early treatment group, n = 10)
Trial: 3481361
Drug: Incision and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incision and drainage with subsequent hospitalization for intravenous antibiotics and hydration
Trial: 29782187
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 3,800 IU daily
Trial: 31880806
Drug: Cochlear implants
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cochlear implants (CIs)
Trial: 18782876
Drug: High-morning hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-morning hydrocortisone (HC) dose (50% of daily dose in the morning)
Trial: 18782876
Drug: High-evening hydrocortisone
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-evening hydrocortisone (HC) dose (50% of daily dose in the evening)
Trial: 11107790
Drug: Phagocytic activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phagocytic activity connected with intracellular oxygen metabolism
Trial: 6370703
Drug: Theophylline (T)
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline (T) 5.0 mg/kg
Trial: 6370703
Drug: Enprofylline (E)
RxNorm normalized name: etofylline
DrugBank: Enprofylline (DB00824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline (E) 1.5 mg/kg
Trial: 29849487
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy (n = 43)
Trial: 17768472
Drug: Topical 10%
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 10% zinc sulphate solution
Trial: 17768472
Drug: Topical 5%
RxNorm normalized name: urea topical 5% topical lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 5% zinc sulphate solution
Trial: 15514406
Drug: Citalopram, 10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram, 10-40 mg/day
Trial: 11580079
Drug: Alendronate (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (5 mg/day for 2 years and then 10 mg/day for 1 year)
Trial: 7633170
Drug: Ovum pickup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovum pickup at 36 hr after hCG injection (group B)
Trial: 7633170
Drug: Ovum pickup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovum pickup at 35 hr after hCG injection (group A)
Trial: 7633170
Drug: Ovum pickup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovum pickup at 37 hr after hCG injection (group C)
Trial: 29183910
Drug: Intensifying treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensifying treatments to three oral agents or insulin regimens
Trial: 29183910
Drug: Insulin alone
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin alone use
Trial: 20843375
Drug: Conventional dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dialysis solution (Stay.safe)
Trial: 20843375
Drug: Neutral pH,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral pH, low GDP dialysis solution (Balance)
Trial: 18993156
Drug: 16-week group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-week group-based aerobic high-intensity interval training model twice weekly for 65 to 80 minutes/day (n = 40)
Trial: 17132385
Drug: Standardised advice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised advice and a tapering off schedule with biweekly follow‐up visits (n = 73)
Trial: 12932090
Drug: Five-day course
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-day course of artesunate plus a 14-day course of high-dose primaquine (0.6 mg/kg, maximum dose = 30 mg) (Group A5 + P)
Trial: 12932090
Drug: Seven-day course
RxNorm normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seven-day course of artesunate plus a 14-day course of high-dose primaquine (Group A7 + P)
Trial: 12932090
Drug: High-dose primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose primaquine (0.6 mg/kg of base a day)
Trial: 14747668
Drug: Diet providing
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet providing an ample protein intake (1.67 g. kg fat-free mass(‐1). d(‐1))
Trial: 14747668
Drug: Diet approximating
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet approximating the mean minimum adult protein requirement (0.71 g. kg fat-free mass(‐1). d(‐1))
Trial: 7760775
Drug: Elemental mercury
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental mercury exposure (mean urinary Hg = 36 micrograms/l)
Trial: 21123958
Drug: Coping training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coping training program with 14 weekly two-hour sessions
Trial: 15126758
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (3 month course of a macrolide antibiotic, douche, and topical steroid)
Trial: 11787915
Drug: Intravenous Syntocinon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Syntocinon (10 iu)
Trial: 11787915
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (500 microg)
Trial: 8196432
Drug: Primary functional
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary functional treatment without external or internal stabilization
Trial: 31728714
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg/day for 11 days)
Trial: 31728714
Drug: Lorlatinib alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorlatinib alone (50 mg, 75 mg, 100 mg)
Trial: 28525543
Drug: Glucose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose placebo (12 g/d)
Trial: 28525543
Drug: Fructan (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructan (12 g/d)
Trial: 28525543
Drug: Galacto-oligosaccharides (GOS,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galacto-oligosaccharides (GOS, 6 g/d)
Trial: 28525543
Drug: Sorbitol (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorbitol (6 g/d)
Trial: 19299839
Drug: Feldenkrais intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Feldenkrais intervention (twice‐weekly group classes over 8 weeks)
Trial: 24944159
Drug: Bosutinib 500
RxNorm normalized name: bosutinib 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 500 mg/d
Trial: 24944159
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg/d
Trial: 23623755
Drug: Ramipril/HCTZ fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril/HCTZ fixed-dose combination (5/25 mg/d) - Group A (test formulation)
Trial: 23623755
Drug: Ramipril/HCTZ fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril/HCTZ fixed-dose combination (5/25 mg/d) - Group B (reference formulation)
Trial: 16996596
Drug: Subthreshold grid
RxNorm normalized name: MINERAL OIL 100 g in 100 mL TOPICAL LIQUID [THE GRID]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subthreshold grid laser treatment (SGLT)
Trial: 29703633
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron (50 mg of sodium ferrous citrate daily; oral group, n = 29)
Trial: 29703633
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron (40 mg of saccharated ferric oxide weekly; IV group, n = 32)
Trial: 22917853
Drug: MAP0004 (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAP0004 (3.0 mg, supratherapeutic dose)
Trial: 17828038
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (200 mg of intravenous erythromycin twice daily + 10 mg of intravenous metoclopramide four times daily)
Trial: 17828038
Drug: Erythromycin alone
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin alone (200 mg of intravenous erythromycin twice daily)
Trial: 15142201
Drug: Intravenous lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lansoprazole in NaCl
Trial: 15142201
Drug: Intravenous lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lansoprazole in polyethylene glycol
Trial: 28414583
Drug: Varenicline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline and behavioral therapy
Trial: 9147709
Drug: Acipimox 250
RxNorm normalized name: acipimox 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox 250 mg thrice daily
Trial: 9147709
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg once daily
Trial: 25332468
Drug: Leu-enriched essential
RxNorm normalized name: Leu
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leu-enriched essential amino acids (3.5 g of Leu)
Trial: 9832483
Drug: Combination diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination diet
Trial: 10489396
Drug: Combination diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination diet in hypertensive subjects
Trial: 8942358
Drug: 15NH4Cl taken
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15NH4Cl taken orally every 20 min for 6 h (total 1.5 g)
Trial: 1656145
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate (1600 mg/day)
Trial: 1656145
Drug: Baclofen (GABAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen (GABAB agonist, 10(‐8)‐10(‐5) M)
Trial: 1656145
Drug: Bicuculline (GABAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicuculline (GABAA antagonist)